Crystalys Gout Drug Trial Expands to Europe, Targeting Unmet Need

By Gary Clark

SAN DIEGO, CA – February 02, 2026 – Crystalys Therapeutics, a biopharmaceutical company focused on chronic inflammatory diseases, has taken a significant step in its quest to bring a new treatment to millions of gout sufferers. The company announced today that the first patients have been dosed in Europe for its pivotal Phase 3 RUBY study, a global trial evaluating its lead candidate, dotinurad.

This expansion marks a critical milestone for a drug that aims to fill a glaring void in the treatment landscape for gout, a painful and debilitating form of inflammatory arthritis. Dotinurad, a once-daily oral medication, is being developed as a second-line therapy for patients who fail to achieve target uric acid levels with the current standard of care, allopurinol. The RUBY study's progress brings a new wave of hope for a large, underserved patient population in Western markets.

"Expanding patient dosing into European sites is a key milestone for the RUBY study and we look forward to continued progress as enrollment advances," said James Mackay, Ph.D., President and Chief Executive Officer of Crystalys Therapeutics, in a statement.

A Critical Gap in Gout Treatment

Gout is the most common form of inflammatory arthritis, affecting millions globally. It arises from hyperuricemia, a condition where excess uric acid in the bloodstream crystallizes in the joints, leading to sudden, excruciating attacks of pain, swelling, and redness. If left undertreated, chronic gout can lead to the formation of tophi—large deposits of uric acid crystals—causing permanent joint damage and severe disability.

For decades, the primary first-line treatment has been allopurinol, a xanthine oxidase inhibitor (XOI) that reduces the body's production of uric acid. While effective for many, an estimated 10-30% of patients either do not respond adequately to allopurinol or cannot tolerate it. In the United States alone, this translates to two to three million patients with inadequately controlled disease.

For these individuals, the path forward is fraught with challenges. The U.S. and European markets currently lack a well-tolerated, approved second-line therapy. The alternative XOI, febuxostat, carries an FDA black box warning due to increased cardiovascular risk. The last-line option, pegloticase, is an infused therapy reserved for the most severe cases and can have significant side effects. This creates a vast treatment chasm, leaving countless patients struggling with chronic pain and progressive joint destruction.

Enter Dotinurad: A Proven Candidate Goes Global

Crystalys Therapeutics aims to bridge this gap with dotinurad. The drug is a next-generation selective urate reabsorption inhibitor (SURI) that works by a different mechanism than allopurinol. It targets URAT1, a transporter in the kidneys, to selectively block the reabsorption of uric acid, thereby promoting its excretion from the body.

While dotinurad is just now entering late-stage trials in the West, it is by no means an unproven entity. The drug, invented by Fuji Yakuhin, has already secured regulatory approval and is marketed as URECE® in Japan, China, the Philippines, and Thailand. This existing track record is backed by robust clinical data from Asian markets, providing a strong foundation for its global development.

In Japanese clinical trials involving over 500 patients, dotinurad demonstrated impressive efficacy and a favorable safety profile. A 12-week Phase 2 study showed a powerful, dose-dependent reduction in serum uric acid levels, with 100% of patients in the 4 mg dose group achieving the target level of 6.0 mg/dL or less. Subsequent Phase 3 studies, lasting up to 58 weeks, confirmed its long-term safety and efficacy, demonstrating non-inferiority to febuxostat. Importantly, clinical studies have suggested that dotinurad does not require dose adjustments for elderly patients or those with mild to moderate renal dysfunction, a common comorbidity in the gout population.

The global Phase 3 RUBY study is a randomized, double-blind, multicenter trial designed to enroll approximately 500 patients with hyperuricemia and gout. Participants will receive a once-daily oral dose of dotinurad for up to 64 weeks, with researchers evaluating its long-term safety and ability to lower uric acid levels.

The Financial Powerhouse Behind the Push

Bringing a drug through global Phase 3 trials is a monumental and costly undertaking, but Crystalys Therapeutics is exceptionally well-positioned to succeed. The company launched in 2022 with a massive $205 million Series A financing round, signaling powerful investor confidence in its strategy and its lead asset.

The funding was co-led by a syndicate of top-tier life science investors, including Novo Holdings, SR One, and co-founder Catalys Pacific. This substantial financial backing provides the company with a long runway to not only complete the RUBY study but also to prepare for potential regulatory submission and commercial launch in the U.S. and Europe. This level of investment underscores the perceived market opportunity and the significant unmet need that dotinurad is poised to address.

Navigating a Competitive Field

Crystalys is entering a dynamic and increasingly competitive market. The global gout therapeutics space was valued at over $3 billion in 2024 and is projected to climb towards $5 billion by 2030, attracting significant R&D investment. While dotinurad is a leading candidate, it is not the only one in the race to become the go-to second-line therapy.

Other companies are also advancing novel treatments. Arthrosi Therapeutics' pozdeutinurad (AR882), another URAT1 inhibitor, has also shown strong results in mid-stage trials and has received FDA Fast Track Designation. The broader pipeline includes over 25 novel drugs from more than 20 companies, exploring various mechanisms such as new XOIs, improved uricase treatments, and anti-inflammatory agents targeting the NLRP3 inflammasome.

Despite the competition, dotinurad's unique profile as a proven therapy in other major markets gives Crystalys a distinct advantage. The expansion of the RUBY study into Europe is a clear signal of the company's intent to establish dotinurad as a global standard of care. Success in this trial could finally provide millions of patients in the West with the effective, safe, and convenient second-line option they have long been waiting for, potentially transforming the management of chronic gout for years to come.